NuCana (NCNA)
1.05
0.03 (2.94%)
At close: Jan 14, 2025, 3:58 PM
1.09
3.73%
After-hours Jan 14, 2025, 07:50 PM EST
undefined% (undefined)
| Bid | 1.01 |
| Market Cap | 4.12M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -14.45 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.14 |
| Volume | 175,575 |
| Avg. Volume (20D) | 167,475 |
| Open | 1.03 |
| Previous Close | 1.02 |
| Day's Range | 1.02 - 1.12 |
| 52-Week Range | 0.96 - 19.40 |
| Beta | undefined |
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary trac...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 28, 2017
Employees 25
Stock Exchange NASDAQ
Ticker Symbol NCNA
Website https://www.nucana.com
Analyst Forecast
According to 2 analyst ratings, the average rating for NCNA stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 2279.14% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
3 months ago ·
Source
-8.41%
NuCana shares are trading higher after the company...
Unlock content with
Pro Subscription
4 months ago ·
Source
+150.79%
NuCana shares are trading higher after the company announced final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
